Hoe verhoudt UDJ's PS Ratio zich tot zijn concurrenten?

UDJ is duur op basis van de Price-To-Sales -ratio ( 0.7 x) vergeleken met het gemiddelde van de peer ( 0.4 x).

Hoe verhoudt UDJ's PS Ratio zich tot andere bedrijven in de European Life Sciences industrie?

UDJ is een goede waarde op basis van de Price-To-Sales -ratio ( 0.7 x) vergeleken met het European Life Sciences -industriegemiddelde ( 4.3 x).

Wat is UDJ's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

UDJ is een goede waarde op basis van de Price-To-Sales -ratio ( 0.7 x) vergeleken met de geschatte eerlijke Price-To-Sales -ratio ( 1.3 x).

Wat is de reële prijs van UDJ als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Onvoldoende gegevens om de reële waarde van UDJ te berekenen voor waarderingsanalyse.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

Applied DNA Sciences (DB:UDJ) - Aandelenkoers, Nieuws & Analyse

UDJ Overzicht aandelen

A biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. Meer informatie

UDJ fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	1/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 18.49% per jaar groeien

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 4.9% per jaar dalen.

Heeft minder dan 1 jaar cash runway

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft geen betekenisvolle marktkapitalisatie ( €4M )

+ 3 meer risico's

Applied DNA Sciences, Inc. Concurrenten

Vitruvia Medical

MUN:991

€1.2m

co.don

XTRA:CNW

€6.5m

Evotec

XTRA:EVT

€1.5b

Biofrontera

XTRA:B8FK

€16.4m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Applied DNA Sciences
Historische aandelenkoersen
Huidige aandelenkoers	US$4.66
52 Week Hoogtepunt	US$33.22
52 Week Laag	US$4.66
Bèta	0.082
11 maand verandering	0%
3 maanden verandering	-21.02%
1 Jaar Verandering	-81.24%
33 jaar verandering	-94.91%
5 jaar verandering	-97.64%
Verandering sinds IPO	-99.98%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	UDJ	DE Life Sciences	DE Markt
7D	0%	0.9%	-0.02%
1Y	-81.2%	2.7%	8.2%

Rendement versus industrie: UDJ presteerde slechter dan de German Life Sciences -sector, die het afgelopen jaar een rendement van 2.7 % opleverde.

Rendement versus markt: UDJ presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 8.2 % opleverde.

Prijsvolatiliteit

Is UDJ's price volatile compared to industry and market?
UDJ volatility
UDJ Average Weekly Movement	n/a
Life Sciences Industry Average Movement	6.1%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van UDJ is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van UDJ in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1983	54	James Hayward	www.adnas.com

Applied DNA Sciences, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Applied DNA Sciences zich tot de beurswaarde?
UDJ fundamentele statistieken
Marktkapitalisatie	€3.78m
Inkomsten(TTM)	-€11.48m
Inkomsten(TTM)	€5.07m

0.7x

P/S-verhouding

-0.3x

Koers/Winstverhouding

Is UDJ overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
UDJ resultatenrekening (TTM)
Inkomsten	US$5.52m
Kosten van inkomsten	US$3.64m
Brutowinst	US$1.88m
Overige uitgaven	US$14.38m
Inkomsten	-US$12.50m

Laatst gerapporteerde inkomsten

Mar 31, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.22
Brutomarge	33.98%
Nettowinstmarge	-226.55%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde UDJ op de lange termijn?

Bekijk historische prestaties en vergelijking

UDJ Overzicht aandelen

Beloningen

Risicoanalyse

Applied DNA Sciences, Inc. Concurrenten

MUN:991

€1.2m

XTRA:CNW

€6.5m

XTRA:EVT

€1.5b

XTRA:B8FK

€16.4m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Applied DNA Sciences, Inc. Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Applied DNA Sciences, Inc. announced that it has received funding

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.499893 million.

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA Sciences, Inc.'s Applied DNA Clinical Labs, LLC Launches Mpox Clade I and Clade II Testing Service

Applied DNA Sciences, Inc. to Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I

Recent updates

Applied DNA Sciences, Inc. Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Applied DNA Sciences, Inc. announced that it has received funding

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.499893 million.

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA Sciences, Inc.'s Applied DNA Clinical Labs, LLC Launches Mpox Clade I and Clade II Testing Service

Applied DNA Sciences, Inc. to Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I

Applied DNA Sciences, Inc. to Report Q3, 2024 Results on Aug 08, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Sep 30, 2024

Applied DNA Sciences Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Applied DNA Sciences, Inc. Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health

Applied DNA Sciences, Inc. has completed a Composite Units Offering in the amount of $12 million.

Applied DNA Sciences, Inc. has completed a Composite Units Offering in the amount of $12 million.

Applied DNA Sciences, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering.

Applied DNA Sciences, Inc. to Showcase Linea DNA and Linea IVT Platforms At 24Th Annual World Vaccine Congress

First quarter 2024 earnings released: US$0.075 loss per share (vs US$0.30 loss in 1Q 2023)

New major risk - Shareholder dilution

Applied DNA Sciences, Inc. to Report Q1, 2024 Results on Feb 08, 2024

Applied DNA Sciences, Inc., Annual General Meeting, Apr 15, 2024

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.436992 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $3.437233 million.

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$0.76 loss per share (vs US$0.93 loss in FY 2022)

Applied DNA Sciences Receives Non-Compliance Notice From Nasdaq

Applied DNA Sciences, Inc. to Report Q4, 2023 Results on Dec 07, 2023

Applied DNA Sciences, Inc. Extends Application of Linea(Tm) Ivt Platform to Sna (Self-Amplifying Mrna)

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $6.397939 million.

Applied DNA Sciences, Inc. Announces Appointment of Beverly Wolgast as Executive Director of Quality and cGMP Programs

Applied DNA Sciences, Inc. Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit

Applied DNA Sciences, Inc. Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.13 loss in 3Q 2022)

Applied DNA Sciences, Inc. to Report Q3, 2023 Results on Aug 10, 2023

Applied DNA Sciences, Inc., Annual General Meeting, Sep 19, 2023

Applied DNA Sciences, Inc. (NasdaqCM:APDN) acquired Spindle Biotech Inc. for $2.8 million.

New major risk - Share price stability

Second quarter 2023 earnings released: EPS: US$0.046 (vs US$0.23 loss in 2Q 2022)

Applied DNA Sciences, Inc. to Report Q2, 2023 Results on May 11, 2023

First quarter 2023 earnings released: US$0.30 loss per share (vs US$0.63 loss in 1Q 2022)

Applied DNA Sciences, Inc. to Report Q1, 2023 Results on Feb 09, 2023

Applied DNA Sciences, Inc. Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA as New Class of DNA-Based Vaccines

Full year 2022 earnings released: US$0.93 loss per share (vs US$2.07 loss in FY 2021)

Insufficient new directors

Applied DNA Sciences, Inc. to Report Q4, 2022 Results on Dec 05, 2022

Applied DNA Sciences, Inc.'s Subsidiary, Applied DNA Clinical Labs, LLC, Launches Monkeypox Testing Service

Applied DNA Submits PCR-Based Monkeypox Virus Diagnostic Test for Approval to New York State Department of Health

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.46 loss in 3Q 2021)

Applied DNA Sciences, Inc. Announces Retirement of John Bitzer from Board of Directors

Applied DNA Sciences, Inc. Launches Initiatives to Expand Awareness of LinearDNA Platform as Alternative to Plasmid DNA for Therapeutic Applications, Revamps LineaRx Website

Applied DNA and Evvivax Announce Peer-Reviewed Publication of Positive Preclinical Data for LinearDNA Platform

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.21 loss in 2Q 2021)

Applied DNA Sciences, Inc. to Report Q2, 2022 Results on May 12, 2022

Applied DNA Sciences, Inc. and EvviVax, S.R.L. Announce Publication of Positive Preclinical Data for LinearDNA™ Platform Approach to Cancer Immunotherapy

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Applied DNA Sciences, Inc. to Report Q1, 2022 Results on Feb 10, 2022

Applied DNA Sciences, Inc. to Deploy Linea™ 1.0 COVID-19 Assay for Rapid Detection of New Omicron Subvariant BA.2

Applied DNA Clinical Labs Receives New York State Department of Health Conditional Approval for Linea™ 2.0 COVID-19 Assay as Laboratory Developed Test

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat